Cargando…
A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
Breakthrough pain, a transitory severe pain with the background of otherwise controlled persistent pain has a prevalence between 52% and 67% in outpatients with cancer. Medications for such sudden-onset pain require non-invasive delivery of a potent and short-acting opioid for rapid pain relief. Alt...
Autor principal: | Freye, Enno |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004632/ https://www.ncbi.nlm.nih.gov/pubmed/21197291 |
Ejemplares similares
-
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
por: Prommer, Eric, et al.
Publicado: (2012) -
Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy
por: Darwish, Mona, et al.
Publicado: (2010) -
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
por: Darbà, Josep, et al.
Publicado: (2013) -
Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to Morphine Sulphate Immediate Release Tablet in Management of Breakthrough Cancer Pain
por: Bhatnagar, Sushma, et al.
Publicado: (2014) -
Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
por: Mercadante, S, et al.
Publicado: (2007)